Pseudoprogression Possible in Enzalutamide-Treated mCRPC – Renal and Urology News
In mCRPC, pseudoprogression or bone scan flare can be misinterpreted as enzalutamide failure and lead to premature discontinuation of therapy.
Related Articles
Metal Mixtures During Pregnancy May Lower Midlife Hypertension Risk
Doubling of vitamin B12 associated with lower systolic and diastolic blood pressure
Metabolic Factors Linked to 10-Year Trajectory of Chronic Musculoskeletal Pain
Certain metabolic factors are associated with the development of chronic musculoskeletal pain, including higher BMI and the presence of diabetes.
Recent Decade Saw No Change in Diabetes Prevalence in US Adults
However, glycemic control worsened, with the trend most pronounced among younger adults aged 20 to 44 years
Anemia, ESA Hyporesponsiveness Tied With Residual Kidney Function Decline in Dialysis
Preservation of residual kidney function is an important goal for patients undergoing dialysis.
For Some Cancers, Black Patients Have Lower Survival Rates Than White Patients
Although overall cancer mortality rates are declining for Black patients, they continue to have higher mortality rates than White patients for some cancers.
Low-Frequency Bladder Vibration Beneficial for UTI in Spinal Cord Injury
Four weeks after LFBV, intervention group had significantly lower urinary leukocytes, postvoid residual volume, fewer signs and symptoms of UTI
Kidney Transplant Fast Track Program Speeds Waitlisting, Reduces Disparities
A simple intervention that fast tracks early testing may improve kidney transplantation rates and disparities.
Americans Borrowed $74 Billion in 2024 to Cover Medical Costs
Survey reveals many Americans worry they will incur medical debt if they experience a major medical event
No Weight Loss Benefit Seen for Neoadjuvant Semaglutide Before Weight Loss Surgery
No benefits seen in terms of weight loss, diabetes remission, surgery safety
Study IDs Post-Transplant Anemia Contributors, Clarifies Role of ESAs
A systematic review and meta-analysis identified factors contributing to post-kidney transplant anemia and the effect of erythropoietin-stimulating agents (ESAs).